提醒

Oragenics Inc. (OGEN)

NYSE American: OGEN · 即時價格 · USD

0.53

+0.00 (0.00%)

收盤時： Aug 18, 2026, 11:51 AM

0.00% (1D)

買價	n/a
市值	2.4M
營收 (ttm)	n/a
淨利（ttm）	-10.08M
貝塔	n/a
EPS (ttm)	-1.42
本益比（ttm）	n/a
正向 PE	-0.05
P/B (ttm)	0.38
P/S (ttm)	n/a
Earnings Date	n/a

賣價	n/a
成交量	6,770
20 日平均成交量	36,240
打開	0.54
上一頁關閉	0.53
日間範圍	0.53 - 0.54
52 週範圍	0.48 - 1.45
分析師	n/a
目標價	n/a
股利	n/a
Ex-股利日期	n/a

關於OGEN

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene ampli...

[閱讀更多]

工業 Biotechnology

部門 Healthcare

IPO 日期 Feb 25, 2004

員工 3

證券交易所 NYSE American

股票代號 OGEN

網站 https://www.oragenics.com

完整的公司簡介

財務表現

Oragenics 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -9.84M，較前期減少 -6.86%。

財務報表

獲利驚喜

Oragenics 已於 May 12, 2023 公布季度財報：

營收的 $0 錯過估計 $0, 與 NaN% YoY 成長.

EPS 的 -42.3 超出估計 47.71, 與 53.01% YoY 成長.

新聞動態

6 月前 · TipRanks

Oragenics previews targeted milestones for 2026

Oragenics (OGEN) previewed its targeted milestones for 2026. Oragenics is advancing its lead candidate ONP-002, a novel intranasal neurosteroid, through clinical studies as the potential first and onl...

6 月前 · TipRanks

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Oragenics (OGEN) announced it has engaged Duck Flats Pharma as its U.S. Investigational New Drug, IND, readiness and regulatory execution partner to support FDA-facing preparation and clinical trial d...

9 月前 · Associated Press Finance

Oragenics: Q3 Earnings Snapshot

SARASOTA, Fla. AP) — Oragenics Inc. OGEN) on Friday reported a loss of $3.1 million in its third quarter.

10 月前 · Pharmaceutical Technology

Oragenics partners Receptor.AI for brain health candidate portfolio

The partnership will harness AI modelling techniques to determine the ideal receptor binding profiles for new compounds.

Oragenics Inc. (OGEN)